Silo Pharma said that it is planning to develop an intranasal formulation of its SPC-15, which includes "ketamine compositions," for the prevention and treatment of stress disorders, including anxiety and PTSD. The formulation was developed at Columbia University under a sponsored research agreement. According to Silo, US Patent no 11,622,948 ("Biomarkers for Efficacy … [Read more...] about Silo Pharma says it will develop intranasal formulation of SPC-15 ketamine for the treatment of stress disorders
Medical
Vistagen says Phase 3 PALISADE-2 trial PH94B fasedienol nasal spray for SAD met primary endpoint
Vistagen has announced that the Phase 3 PALISADE-2 public speaking challenge trial of PH94B fasedienol nasal spray in subjects with social anxiety disorder met its primary and secondary endpoints. The company announced the initiation of PALISADE-2 in September 2021 and then paused the trial in mid-2022 after PALISADE-1 failed to meet its primary endpoint. The trial … [Read more...] about Vistagen says Phase 3 PALISADE-2 trial PH94B fasedienol nasal spray for SAD met primary endpoint
Inimmune initiates Phase 1/1b trial of INI-2004 intranasal TLR4 agonist
Missoula, Montana-based Inimmune Corporation has announced the initiation of Phase 1/1b trial of its INI-2004 intranasal toll-like receptor 4 agonist, which the company is developing for the treatment of allergic rhinitis. According to the company, the Phase 1 SAD portion of the study, which is taking place in Australia, will enroll healthy volunteers and patients … [Read more...] about Inimmune initiates Phase 1/1b trial of INI-2004 intranasal TLR4 agonist
Krystal Biotech says that it will develop an inhaled formulation of its KB707 gene therapy for the treatment of solid tumors
Krystal Biotech announced that it will develop injectable and inhaled versions of its KB707 gene therapy for the treatment of malignant solid tumors, including metastatic cancer. The company said that it intends to amend an existing IND to add a clinical trial of the inhaled formulation by the end of the year, with the trial expected to begin by mid-2024. Krystal … [Read more...] about Krystal Biotech says that it will develop an inhaled formulation of its KB707 gene therapy for the treatment of solid tumors
Insilico Medicine says it intends to file IND for ISM001-055 inhalation solution for IPF
Insilico Medicine, which claims to be "a generative artificial intelligence (AI)-driven clinical-stage drug discovery company," said that it is "the first AI drug discovery company to venture into nebulized formulations" as the company plans to file an IND for its ISM001-055 inhalation solution for the treatment of idiopathic pulmonary fibrosis. According to the … [Read more...] about Insilico Medicine says it intends to file IND for ISM001-055 inhalation solution for IPF
Lupin launches Luforbec beclometasone / formoterol MDI in Germany
Lupin announced that its German subsidiary Hormosan Pharma has launched Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Germany. According to Lupin, the price of the MDI, which is a generic of Chiesi's Foster (Fostair), will be set at just over half the reference price. Luforbec has been available in the UK since 2021. Hormosan … [Read more...] about Lupin launches Luforbec beclometasone / formoterol MDI in Germany
Zambon says COVID-disrupted Phase 3 PROMIS-II trial of its CMS I-neb nebulized dry powder colistimethate sodium for NCFB failed to meet its primary endpoint
Zambon said that the Phase 3 PROMIS-II trial of its CMS I-neb inhaled dry powder colistimethate sodium for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult patients with chronic P. aeruginosa lung infections failed to meet its primary endpoint due to disruptions caused by the COVID-19 pandemic; those disruptions also resulted in the early … [Read more...] about Zambon says COVID-disrupted Phase 3 PROMIS-II trial of its CMS I-neb nebulized dry powder colistimethate sodium for NCFB failed to meet its primary endpoint
Tonix announces initiation of Phase 2 trial of TNX-1900 intranasal potentiated oxytocin for social anxiety disorder
Tonix Pharmaceuticals announced that researchers at the University of Washington have initiated a placebo-controlled Phase 2 trial of Tonix's TNX-1900 potentiated intranasal oxytocin for social anxiety disorder (SAD). The company said that the study is expected to enroll 50 subjects with diagnosed SAD and 50 matched healthy subjects. Researchers will evaluate how a … [Read more...] about Tonix announces initiation of Phase 2 trial of TNX-1900 intranasal potentiated oxytocin for social anxiety disorder
Tonix initiates Phase 2 trial of TNX-1900 intranasal potentiated oxytocin for the treatment of obesity in pediatric patients
Tonix Pharmaceuticals has announced the initiation of the Phase 2 POWER study of its TNX-1900 potentiated oxytocin nasal spray in subjects aged 12-18 whose body mass index (BMI) is in the 95th percentile or higher for their age and gender. The study, which is taking place at Massachusetts General Hospital, is expected to enroll 75 participants who will use either … [Read more...] about Tonix initiates Phase 2 trial of TNX-1900 intranasal potentiated oxytocin for the treatment of obesity in pediatric patients
Pendopharm recalls one lot of Rhinaris Nasal Mist in Canada
Health Canada announced that Pharmascience's Pendopharm division is recalling one lot of Rhinaris Nasal Mist saline nasal spray after "testing showed that the preservative in the product may not be as effective as expected." Specifically, the agency said that testing indicated the potential for P. aeruginosa to grow in the product. The lot affected by the recall is … [Read more...] about Pendopharm recalls one lot of Rhinaris Nasal Mist in Canada